Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RUXexia: Ruxolitinib for Cancer Cachexia
NCT02072057Phase 2Terminated
- Sponsor
- Kantonsspital Aarau
- Start
- Apr 2014
- Primary completion
- Nov 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ruxolitinib in cancer cachexia, sponsored by Kantonsspital Aarau. Primary endpoint: Body weight at 3 months. Started Apr 2014; status: terminated.
02
Drugs
03
Conditions
cancer cachexia
Beyond the preview
Go deeper on NCT02072057.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02072057.